
4DMT unveils dose exploration data in wet AMD; Exicure installs new C-suite exec
4D Molecular Therapeutics has some new data from a Phase I/II trial testing a wet AMD candidate in different dose levels.
The biotech reported Thursday interim data from three doses of genetic medicine candidate 4D-150 in 15 patients, delivered intravitreally. Beyond all the doses being well-tolerated, 4D said that all three doses showed “clinical activity,” which included metrics such as stable visual acuity and “stable or improved retinal edema and thickness.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.